NEW ORLEANS — In a subgroup analysis of the ASCENT-COPD trial, treatment with the long-acting antimuscarinic bronchodilator aclidinium bromide reduced the risk for new exacerbations compared with placebo in patients with moderate to very severe COPD and high cardiovascular risk, regardless of prior exacerbations.
Further, the data highlight equivalent safety in terms of major adverse CV events and mortality, Robert Wise, MD, FCCP, professor of medicine at Johns Hopkins University School of Medicine, told Healio Pulmonology.
This educational activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.